Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
I'm PortAI, I can summarize articles.
Wedbush analyst Yun Zhong has reaffirmed a Buy rating on Rocket Pharmaceuticals (RCKT) with a price target of $16.00. Zhong, who has an average return of -9.0% and a 42.50% success rate, also covers other healthcare stocks. Additionally, LifeSci Capital's Cory Jubinville issued a Buy rating for Rocket Pharmaceuticals today, while Needham maintained a Hold rating on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments